ACXP
Acurx Pharmaceuticals, Inc. [ACXP] Stock Forecast
Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
RSI : 000
ACXP Stock Summary
Top ACXP Correlated Resources
ACXP
Top 10 Correlated ETFs
ACXP
Top 10 Correlated Stocks
ACXP
In the News
ACXP Financial details
Company Rating
-
Market Cap
25.61M
Income
-14.58M
Revenue
0
Book val./share
-
Cash/share
-
Dividend
-
Dividend %
-
Employees
4
Optionable
No
Shortable
Yes
Earnings
10 May 2024
P/E
-7.73
Forward P/E
-
PEG
-28.86
P/S
-
P/B
14.61
P/C
-
P/FCF
-8.57
Quick Ratio
2.19
Current Ratio
2.22
Debt / Equity
-
LT Debt / Equity
-
-
-
EPS (TTM)
-1.15
EPS next Y
-
EPS next Q
-
EPS this Y
2.68%
EPS next Y
-
EPS next 5Y
-
EPS last 5Y
-
Revenue last 5Y
-
Revenue Q/Q
-
EPS Q/Q
58.33%
-
-
-
-
SMA20
-18.18%
SMA50
-52.63%
SMA100
-77.78%
Inst Own
-
Inst Trans
-
ROA
-104%
ROE
-131%
ROC
-879.31%
Gross Margin
-
Oper. Margin
-
Profit Margin
-
Payout
-
Shs Outstand
-
Shs Float
-
-
-
-
-
Target Price
-
52W Range
1.17-8.82
52W High
-95.39%
52W Low
-63.1%
RSI
40.02
Rel Volume
0.72
Avg Volume
159.98K
Volume
115.77K
Perf Week
12.23%
Perf Month
-19.31%
Perf Quarter
-80.16%
Perf Half Y
-81.17%
-
-
-
-
Beta
-1.897
-
-
Volatility
0.02%, 0.05%
Prev Close
-1.02%
Price
0.369
Change
-7.75%
Company Profile
- Volume Average 159.98K
- Market Capitalization 25.61M
- Employee 4
- CEO Mr. David P. Luci CPA, Esq., J.D.
- Headquarters Staten Island,NY,US
- IPO Date 2021-06-25
-
Website
https://www.acurxpharma.com 
Acurx Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, develops antibiotics to treat bacterial infections. Its lead antibiotic candidate is ibezapolstat, a novel mechanism of action that targets the polymerase IIIC enzyme that has completed Phase II clinical trial to treat patients with clostridium difficile infections. The company is also developing ACX-375C, a potential oral and parenteral treatment targeting gram-positive bacteria, including methicillin-resistant staphylococcus aureus, vancomycin-resistant enterococcus, and penicillin-resistant streptococcus pneumoniae. Acurx Pharmaceuticals, Inc. was incorporated in 2017 and is headquartered in Staten Island, New York.
